BCEL Projected Dividend Yield

Cl A Com/Atreca Inc ( OTCBB : BCEL )

Atreca is a clinical-stage biopharmaceutical company utilizing its platform primarily to discover and develop antibody-based immunotherapeutics to treat a range of solid tumor types. Co.'s primary product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. Co. owns worldwide rights to ATRC-101.

20 YEAR PERFORMANCE RESULTS

BCEL Dividend History Detail
BCEL Dividend News
BCEL Competitors News
# of Shares: 0 Closing Price: 0.08 Current Market Value: 0.00 Cost Basis: 0.00 Date Acquired:
Dividend Cash Flow
Year Annual Dividend Dividend Growth # of Shares Annual Dividend Income Yield On Cost %
2014 0.00 0% 0 $ 0.00 0.00%
2015 0.00 0% 0 $ 0.00 0.00%
2016 0.00 0% 0 $ 0.00 0.00%
2017 0.00 0% 0 $ 0.00 0.00%
2018 0.00 0% 0 $ 0.00 0.00%
2019 0.00 0% 0 $ 0.00 0.00%
2020 0.00 0% 0 $ 0.00 0.00%
2021 0.00 0% 0 $ 0.00 0.00%
2022 0.00 0% 0 $ 0.00 0.00%
2023 0.00 0% 0 $ 0.00 0.00%
2024 0.00 0% 0 $ 0.00 0.00%
2025 0.00 0% 0 $ 0.00 0.00%
2026 0.00 0% 0 $ 0.00 0.00%
2027 0.00 0% 0 $ 0.00 0.00%
2028 0.00 0% 0 $ 0.00 0.00%
2029 0.00 0% 0 $ 0.00 0.00%
2030 0.00 0% 0 $ 0.00 0.00%
2031 0.00 0% 0 $ 0.00 0.00%
2032 0.00 0% 0 $ 0.00 0.00%
2033 0.00 0% 0 $ 0.00 0.00%
2034 0.00 0% 0 $ 0.00 0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection)
0.00
Year
Declaration Date
Ex-Dividend Date
Record Date
Payable Date
Dividend $ Amount
Total:
0.0000
X
Search Dividend Investor